Back to Clinical Trials Overview

Your search for "Depression" returned 21 results:


A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase IIb Efficacy and Safety Study of Adjunctive AZD6765 in Patients with Major Depressive Disorder (MDD) and a History of Inadequate Response to Antidepressants
Principal Investigator(s): Dan Iosifescu, MD

Optimization of IV Ketamine in Treatment-Resistant Major Depression
Principal Investigator(s): Dan Iosifescu, MD

Center for Achieving & Sustaining Improved Health/Harlem Project 2 -Patient Education to Reduce Postpartum Depressive Symptoms Among Minority Women
Principal Investigator(s): Howell, Elizabeth A

Double-Blind, Proof-of-Concept (POC) Trial of Low Field Magnetic Stimulation (LFMS) Augmentation of Antidepressant Therapy in Treatment-Resistant Depression (TRD)
Principal Investigator(s): James Murrough

Ketamine Plus Lithium as a Novel Pharmacotherapeutic Strategy in Treatment Resistant Depression
Principal Investigator(s): James Murrough, MD

Intravenous (IV) Ketamine in Treatment-Resistant Bipolar Depression (TRBD)
Principal Investigator(s): Murrough, James

A multi-center, randomized, double-blind, placebo-controlled, parallel-group study to investigate the efficacy and safety of RO4995819 versus placebo, as adjunctive therapy in patients with major depressive disorder having inadequate response to ongoing antidepressant treatment
Principal Investigator(s): Dan Iosifescu, MD

A Prospective, Double Blind, Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the H1-Coil deep Transcranial Magnetic Stimulation (TMS) in conjunction with mood stabilizers in Subjects with Bipolar Depression
Principal Investigator(s): Dan Iosifescu

Dopamine and Motivation in Depression
Principal Investigator(s): Dan Iosifescu

Cognitive Training for Depression
Principal Investigator(s): Brian M. Iacoviello

Targeting the NMDA Glutamate Receptor as a Novel Antidepressant Strategy: A Pilot Clinical Trial of Nuedexta in Treatment-Resistant Major Depression
Principal Investigator(s): James Murrough

A Phase 2, Multicenter, Double-blind, Parallel-group, Randomized, Placebo-controlled, Forced-dose Titration, Dose-ranging Efficacy and Safety Study of SPD489 in Combination with an Antidepressant in the Treatment of Adults with Major Depressive Disorder with Inadequate Response to Prospective Treatment with an Antidepressant
Principal Investigator(s): Dan Iosifescu, MD

A Proof-Of-Concept Clinical Trial of a Novel KCNQ Potentiator in Major Depressive Disorder
Principal Investigator(s): James Murrough

Double-blind, Randomized Study of Extended-release Quetiapine Fumarate (Seroquel XR) in the Treatment of Patients with Comorbid Depression and Anxiety Disorder
Principal Investigator(s): Hirschowitz, Jack

A Double-Blind, Paroxetine- and Placebo-Controlled Study of 50 mg/day and 100 mg/day of EB-1010 among Outpatients with Major Depressive Disorder Who have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
Principal Investigator(s): Dan Iosifescu, MD

Intranasal (IN) Ketamine in Treatment Resistant Depression (TRD)
Principal Investigator(s): James Murrough, MD

Evaluation of Low Emission Neosync EEG Synchronized TMS Technology for the Treatment of Major Depressive Disorder: A Multicenter Randomized, Double-Blind, Sham-Controlled Trial
Principal Investigator(s): Dan Iosifescu, MD

An fMRI Study of Ketamine in Treatment-Resistant Depression
Principal Investigator(s): Murrough, James

Minocycline for Bipolar Disorder
Principal Investigator(s): Dan Iosifescu, MD

Screening for Depression in Patients with Multiple Sclerosis
Principal Investigator(s): Ben-Zacharia, Aliza

Preparation to Reduce Postpartum Depressive Symptoms
Principal Investigator(s): Howell, Elizabeth A